hu-mik-beta-1
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2004 (NCT00076180)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2 receptor beta chainINHIBITOR
IL2RB inhibitor
- Interleukin-15INHIBITOR
IL15 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109610 ↗
Also known as
- hu-mik-beta-1
- humik-beta-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01893775 | Phase 1 | Jun 11, 2013 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00076843 | Phase 1 | Jan 29, 2004 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00076180 | Phase 1 | Jan 6, 2004 | National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2004 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1